Power, phaco time reduced in second half of surgery
June 15th 2011The venturi vacuum modality associated with a proprietary phacoemulsification system seems to be more efficient than its counterpart peristaltic system, with reductions in power and phaco time of 20% and 14% respectively, in 104 cases.
System for cataract surgery nets positive initial outcomes
June 15th 2011Intra-operative use of on-screen image guidance with a high-definition three-dimensional surgical microscope system is showing promise for improving the precision and predictability of various maneuvers during small-incision cataract surgery.
Investigational drug voclosporin safe, effective for noninfectious uveiti
June 15th 2011The investigational drug voclosporin has shown positive effects compared with placebo in the management of uveitis in pivotal phase III clinical trials as an oral corticosteroid-sparing drug in patients with clinically quiescent noninfectious uveitis.
Cataract surgery benefits from femtosecond laser
June 15th 2011Femtosecond laser-assisted cataract surgery seems to be a major step forward as a result of the added safety and precision that the laser confers, such as to the creation of the incision, relaxing incisions, capsulorhexis, and nuclear removal steps.
Bandage for cataract surgery patients meets primary endpoints in U.S. trial
June 15th 2011Results of a randomized, controlled U.S. pivotal trial of cataract surgery patients confirmed the efficacy and safety of a novel topical ocular bandage for protecting clear corneal incisions and minimizing postoperative pain.
NICE recommends dexamethasone implant
June 15th 2011In final draft guidance, the National Institute for Health and Clinical Excellence (NICE) here has recommended an intravitreal implant that delivers 0.7 mg of dexamethasone via an applicator (Ozurdex, Allergan) for the treatment of macular edema (ME) due to central retinal vein occlusion and also for branch retinal vein occlusionin cases in which laser photocoagulation is neither beneficial nor appropriate.
EC grants approval for ranibizumab
June 15th 2011The European Commission (EC) has approved a new indication for ranibizumab (Lucentis, marketed by Genentech in the United States and Novartis in the rest of the world): treating patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). The action makes ranibizumab the first anti-vascular endothelial growth factor (VEGF) therapy licensed for the treatment of both BRVO and CRVO in the European Union.